-
Did Improper Practices Affect Growth Trends For Intercept Pharma's Drugs?
Tuesday, September 12, 2017 - 12:05pm | 298Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) plummeted to a new 52-week low of $90.53 Tuesday morning before recovering a few dollars per share in reaction to a warning letter from the company to physicians. The letter cautioned against overdosing certain patients suffering from primary...
-
Abeona Therapeutics Enrolls Its First Patient In Phase 2A Study
Monday, September 26, 2016 - 2:36pm | 361Read More...Cantor Fitzgerald reiterated its Buy rating and $21 as the price target for Abeona Therapeutics Inc (NASDAQ: ABEO) shares. The firm's move comes on the heels of the company announcing enrollment of patients in phase 2A study following the positive results from its Phase one trial. Analysts Elemer...



